SNSE Quote, Financials, Valuation and Earnings

Genprex has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat Genprex's return on equity of --.

Sensei Biotherapeutics has a consensus price target of $4.13, signalling upside risk potential of 631.13%. On the other hand Genprex has an analysts' consensus of $7.50 which suggests that it could grow by 941.67%. Given that Genprex has higher upside potential than Sensei Biotherapeutics, analysts believe Genprex is more attractive than Sensei Biotherapeutics.

Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Genprex has a beta of -1.302, suggesting its less volatile than the S&P 500 by 230.243%.

Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genprex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. Genprex pays out -- of its earnings as a dividend.

Sensei Biotherapeutics quarterly revenues are --, which are smaller than Genprex quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is lower than Genprex's net income of -$4.3M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while Genprex's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for Genprex. Usually stocks with elevated PS ratios are considered overvalued.

IN8bio has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat IN8bio's return on equity of --.

Sensei Biotherapeutics has a consensus price target of $4.13, signalling upside risk potential of 631.13%. On the other hand IN8bio has an analysts' consensus of $4.75 which suggests that it could grow by 1503.65%. Given that IN8bio has higher upside potential than Sensei Biotherapeutics, analysts believe IN8bio is more attractive than Sensei Biotherapeutics.

Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IN8bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IN8bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. IN8bio pays out -- of its earnings as a dividend.

Sensei Biotherapeutics quarterly revenues are --, which are smaller than IN8bio quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is lower than IN8bio's net income of -$7.1M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while IN8bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for IN8bio. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Sensei Biotherapeutics's net margin of -49.65%. Sensei Biotherapeutics's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Sensei Biotherapeutics has a consensus price target of $4.13, signalling upside risk potential of 631.13%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 408.46%. Given that Sensei Biotherapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Sensei Biotherapeutics is more attractive than NovaBay Pharmaceuticals.

Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Sensei Biotherapeutics quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Sensei Biotherapeutics's net income of -$7.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus 0.08x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Relmada Therapeutics has a net margin of -- compared to Sensei Biotherapeutics's net margin of --. Sensei Biotherapeutics's return on equity of -- beat Relmada Therapeutics's return on equity of --.

Sensei Biotherapeutics has a consensus price target of $4.13, signalling upside risk potential of 631.13%. On the other hand Relmada Therapeutics has an analysts' consensus of -- which suggests that it could grow by 131.85%. Given that Sensei Biotherapeutics has higher upside potential than Relmada Therapeutics, analysts believe Sensei Biotherapeutics is more attractive than Relmada Therapeutics.

Sensei Biotherapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Relmada Therapeutics has a beta of 0.513, suggesting its less volatile than the S&P 500 by 48.738%.

Sensei Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relmada Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sensei Biotherapeutics pays -- of its earnings as a dividend. Relmada Therapeutics pays out -- of its earnings as a dividend.

Sensei Biotherapeutics quarterly revenues are --, which are smaller than Relmada Therapeutics quarterly revenues of --. Sensei Biotherapeutics's net income of -$7.3M is higher than Relmada Therapeutics's net income of -$21.7M. Notably, Sensei Biotherapeutics's price-to-earnings ratio is -- while Relmada Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sensei Biotherapeutics is -- versus -- for Relmada Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.